Irina E. Efremova
Moscow, MOW, Russian Federation
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
Gut Microbiota and Cytokine Profile in Cirrhosis.
Journal: Journal of clinical and translational hepatology
Published: March 08, 2024
Presepsin as a biomarker of bacterial translocation and an indicator for the prescription of probiotics in cirrhosis.
Journal: World journal of hepatology
Published: January 14, 2024
Gut Microbiota and Biomarkers of Intestinal Barrier Damage in Cirrhosis.
Journal: Microorganisms
Published: January 07, 2024
Efficacy and Safety of a Probiotic Containing Saccharomyces boulardii CNCM I-745 in the Treatment of Small Intestinal Bacterial Overgrowth in Decompensated Cirrhosis: Randomized, Placebo-Controlled Study.
Journal: Journal of clinical medicine
Published: January 02, 2024
Gut Microbiota and Biomarkers of Endothelial Dysfunction in Cirrhosis.
Journal: International journal of molecular sciences
Published: December 28, 2023
Gut Dysbiosis and Hemodynamic Changes as Links of the Pathogenesis of Complications of Cirrhosis.
Journal: Microorganisms
Published: August 11, 2023
Epidemiology of small intestinal bacterial overgrowth.
Journal: World journal of gastroenterology
Published: March 16, 2023
Small Intestinal Bacterial Overgrowth Is Associated with Poor Prognosis in Cirrhosis.
Journal: Microorganisms
Published: February 21, 2023
Effect of probiotics on hemodynamic changes and complications associated with cirrhosis: A pilot randomized controlled trial.
Journal: World journal of hepatology
Published: February 15, 2022
Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19).
Journal: European cytokine network
Published: August 04, 2021
Last Updated: 09/26/2026